论文部分内容阅读
目的:研究同型半胱氨酸和新蝶呤血清水平与妇科肿瘤的关系。方法:对18例妇科肿瘤患者的血清同型半胱氨酸、半胱氨酸及新蝶呤水平进行分析,并与体内B族维生素(叶酸、B12)状态进行相关性研究。结果:所有患者同型半胱氨酸含量在正常含量上限内,3例(17%)患者在正常含量上限之上,所有患者的半胱氨酸含量(中位数234μM)均低于正常值,维生素B12含量(中位数259 pM)在正常值的最低限附近,13例患者(72%)血清中新蝶呤的含量在显著增加;同型半胱氨酸的含量与叶酸含量呈现负相关(γs=-0.605,P<0.01),与半胱氨酸含量升高有统计学相关性(γs=-0.457,P<0.06)。结论:同型半胱氨酸和新蝶呤能够作为潜在的肿瘤标志物用于妇科肿瘤疾病的筛查和预后表征。
Objective: To study the relationship between serum levels of homocysteine and neopterin and gynecological tumors. Methods: Serum levels of homocysteine, cysteine and neopterin were analyzed in 18 patients with gynecologic oncology. The levels of B vitamins (folic acid, B12) in the patients were analyzed. Results: All patients had a homocysteine level within the upper limit of normal, 3 (17%) above the upper limit of normal, and all patients had a lower cysteine (median, 234 μM) than normal, Vitamin B12 levels (median 259 pM) showed a significant increase in neopterin levels in serum of 13 patients (72%) around the lowest normal; the level of homocysteine was negatively correlated with folic acid ( γs = -0.605, P <0.01), and there was a statistically significant correlation with the increase of cysteine content (γs = -0.457, P <0.06). Conclusion: Homocysteine and neopterin can be used as potential tumor markers in the screening and prognosis of gynecologic oncology diseases.